Literature DB >> 22503775

Biomarkers of dementia: comparison of electrochemiluminescence results and reference ranges with conventional ELISA.

Axel Regeniter1, Jens Kuhle, Thomas Baumann, Marc Sollberger, Markus Herdener, Ursula Kunze, Michael C Camuso, Andreas U Monsch.   

Abstract

We compared the performance of the Meso Scale Diagnostics electrochemiluminescence (MSD) multiplex assay for t-tau and p-tau(231), originally developed for measurement of brain cell extract and tissue cultures, with the established standard method, the Innogenetics ELISA for total and p-tau(181). The methods were also clinically evaluated with 120 samples from our mono center population. The established Innogenetics ELISA procedures have been well optimized to measure patient samples in the normal and pathological range. Compared to the MSD they were superior in the limit of detection for total as well as p-tau. The obtained reference values for our normal controls were in the upper third of the published studies. Innogenetics tau, Innogenetics p-tau(181) and MSD t-tau differentiated the Alzheimer's (n=44) and minimal impairment group (MCI, n=39) from normal controls (n=37), but the MCI group was not statistically different from the normal controls. The MSD multiplex assay measured t-tau adequately but p-tau(231) could not differentiate normal from pathological results in CSF due to the high limit of detection. Both procedures however, have to be further standardized and complemented by adequate internal and external quality control schemes to qualify for routine analysis in a medical laboratory.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22503775     DOI: 10.1016/j.ymeth.2012.03.019

Source DB:  PubMed          Journal:  Methods        ISSN: 1046-2023            Impact factor:   3.608


  5 in total

1.  CD44 expression in endothelial colony-forming cells regulates neurovascular trophic effect.

Authors:  Susumu Sakimoto; Valentina Marchetti; Edith Aguilar; Kelsey Lee; Yoshihiko Usui; Salome Murinello; Felicitas Bucher; Jennifer K Trombley; Regis Fallon; Ravenska Wagey; Carrie Peters; Elizabeth L Scheppke; Peter D Westenskow; Martin Friedlander
Journal:  JCI Insight       Date:  2017-01-26

2.  Does CSF p-tau181 help to discriminate Alzheimer's disease from other dementias and mild cognitive impairment? A meta-analysis of the literature.

Authors:  Wei Tang; Qiong Huang; Yu-You Yao; Yan Wang; Yi-Le Wu; Zheng-Yu Wang
Journal:  J Neural Transm (Vienna)       Date:  2014-05-10       Impact factor: 3.575

3.  Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.

Authors:  Jonathan Spiegel; Elizabeth Pirraglia; Ricardo S Osorio; Lidia Glodzik; Yi Li; Wai Tsui; Leslie A Saint Louis; Catherine Randall; Tracy Butler; Jinfeng Xu; Raymond P Zinkowski; Henrik Zetterberg; Juan Fortea; Silvia Fossati; Thomas Wisniewski; Peter Davies; Kaj Blennow; Mony J de Leon
Journal:  J Alzheimers Dis       Date:  2016       Impact factor: 4.472

Review 4.  Amyloid Beta and Tau as Alzheimer's Disease Blood Biomarkers: Promise From New Technologies.

Authors:  Lih-Fen Lue; Andre Guerra; Douglas G Walker
Journal:  Neurol Ther       Date:  2017-07-21

5.  Comparison of two commercial enzyme-linked immunosorbent assays for cerebrospinal fluid measurement of amyloid β1-42 and total tau.

Authors:  Mirjana Babić; Zeljka Vogrinc; Andrea Diana; Nataša Klepac; Fran Borovečki; Patrick R Hof; Goran Simić
Journal:  Transl Neurosci       Date:  2013-06       Impact factor: 1.757

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.